Mayne Pharma Group Limited (ASX:MYX)
Australia · Delayed Price · Currency is AUD 3.270
+0.040 (1.24%)
Sep 2, 2026, 11:33 AM AEST
Mayne Pharma Group Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 383.68 | 408.1 | 388.4 | 183.59 | 157.15 | |
Revenue Growth | -5.98% | 5.07% | 111.56% | 16.82% | -60.79% |
Cost of Revenue | 135.61 | 160.82 | 169.62 | 100.1 | 85.58 |
Gross Profit | 248.07 | 247.27 | 218.78 | 83.49 | 71.57 |
Selling, General & Admin | 253.89 | 251.4 | 276.38 | 251.19 | 181.89 |
Research & Development | 20.75 | 17.91 | 20.24 | 15.73 | 12.21 |
Operating Expenses | 274.64 | 269.3 | 296.61 | 266.92 | 194.1 |
Operating Income | -26.57 | -22.03 | -77.84 | -183.43 | -122.53 |
Interest Expense | -5.31 | -5.01 | -4.7 | -10.42 | -10.7 |
Interest & Investment Income | 3.68 | 4.91 | 7.07 | 6.72 | 0.46 |
Currency Exchange Gain (Loss) | -5.9 | 2.13 | -0.53 | -9.52 | 0.85 |
Other Non Operating Income (Expenses) | -33.83 | -33.07 | -29.19 | -13.98 | -16 |
EBT Excluding Unusual Items | -67.92 | -53.07 | -105.2 | -210.63 | -147.91 |
Merger & Restructuring Charges | -4.74 | -1.63 | -0.89 | -12.15 | -5.01 |
Gain (Loss) on Sale of Assets | - | - | - | - | 3.74 |
Asset Writedown | -0.17 | - | - | -69.18 | -68.29 |
Legal Settlements | -17.01 | -12.05 | -1.33 | -5.09 | -2.89 |
Other Unusual Items | 125.59 | -16.56 | -82.67 | 23.9 | 74.77 |
Pretax Income | 35.76 | -83.3 | -190.09 | -269.7 | -145.59 |
Income Tax Expense | 4.56 | 6.78 | -21.47 | 47.75 | 74.5 |
Earnings From Continuing Operations | 31.2 | -90.07 | -168.62 | -317.44 | -220.09 |
Earnings From Discontinued Operations | -6.73 | -3.77 | -5.61 | 434.6 | -71.81 |
Net Income to Company | 24.47 | -93.84 | -174.23 | 117.16 | -291.89 |
Minority Interest in Earnings | - | - | - | 0.09 | 10.61 |
Net Income | 24.47 | -93.84 | -174.23 | 117.25 | -281.29 |
Net Income to Common | 24.47 | -93.84 | -174.23 | 117.25 | -281.29 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 80 | 79 | 80 | 82 | 82 |
Shares Outstanding (Diluted) | 106 | 79 | 80 | 82 | 82 |
Shares Change | 34.30% | -0.60% | -3.11% | -0.15% | 4.74% |
EPS (Basic) | 0.31 | -1.19 | -2.19 | 1.43 | -3.42 |
EPS (Diluted) | 0.21 | -1.19 | -2.19 | 1.43 | -3.42 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 10.92 | 5.19 | -23.25 | -51.05 | -17.22 |
Free Cash Flow Per Share | 0.10 | 0.07 | -0.29 | -0.62 | -0.21 |
Gross Margin | 64.66% | 60.59% | 56.33% | 45.48% | 45.54% |
Operating Margin | -6.93% | -5.40% | -20.04% | -99.92% | -77.97% |
Profit Margin | 6.38% | -22.99% | -44.86% | 63.87% | -179.00% |
Free Cash Flow Margin | 2.85% | 1.27% | -5.99% | -27.81% | -10.96% |
EBITDA | 33.11 | 42.08 | -14.5 | -116.53 | -46.34 |
EBITDA Margin | 8.63% | 10.31% | -3.73% | -63.48% | -29.49% |
D&A For EBITDA | 59.67 | 64.11 | 63.33 | 66.9 | 76.19 |
EBIT | -26.57 | -22.03 | -77.84 | -183.43 | -122.53 |
EBIT Margin | -6.93% | -5.40% | -20.04% | -99.92% | -77.97% |
Effective Tax Rate | 12.75% | - | - | - | - |
Revenue as Reported | 383.68 | 408.1 | 388.4 | 183.59 | 157.15 |